^
    Back
    Association details:
    Biomarker:ERBB3 expression
    Cancer:Pancreatic Cancer
    Drug:Perjeta (pertuzumab) (HER2 dimerization inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

    Excerpt:
    HER3 is essential for pertuzumab efficacy in HER2low-expressing pancreatic cancer and HER3 expression might be a predictive biomarker of pertuzumab efficacy in such cancers.
    DOI:
    10.18632/oncotarget.2231